The 2016 revision of the WHO classification of lymphoid neoplasms includes new entities along with a clearer definition of provisional and definitive subtypes based on better understanding of the molecular drivers of lymphomas. These changes impact current treatment paradigms and provide a framework for future clinical trials. Additionally, this update recognizes several premalignant or predominantly indolent entities and underscores the importance of avoiding unnecessarily aggressive treatment in the latter subsets.
Keywords: ALK-negative anaplastic large cell lymphoma (ALCL); BCL6 translocations; Burkitt lymphoma; Chronic lymphocytic leukemia (CLL); Diffuse large B cell lymphoma (DLBCL); Double hit lymphoma; Follicular lymphoma; High grade B cell lymphoma NOS; Lymphoplasmacytic lymphoma; Mantle cell lymphoma; Non-Hodgkin lymphoma; Waldenström macroglobulinemia.